Adipose-derived mesenchymal stem cells ameliorate hyperglycemia through regulating hepatic glucose metabolism in type 2 diabetic rats

详细信息    查看全文

• 作者：Min Xie^a ; ¹ ; Hao Jie Hao^b ; ¹ ; Yu Cheng^a ; Zong Yan Xie^a ; Ya Qi Yin^a ; Qi Zhang^a ; Jie Qing Gao^a ; Hong Yu Liu^c ; Yi Ming Mu^a ; ^{muyiming@301hospital.com.cn} ; Wei Dong Han^b ; ^{hanwdrsw69@yahoo.com}
• 关键词：Mesenchymal stem cells ; Hyperglycemia ; Insulin resistance ; Type 2 diabetes mellitus ; Liver
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2017
• 出版时间：29 January 2017
• 年：2017
• 卷：483
• 期：1
• 页码：435-441
• 全文大小：1773 K
• 卷排序：483

文摘

Infusion of mesenchymal stem cells (MSCs) has been identified in the rapid alleviation in hyperglycemia of diabetic individuals, but the mechanism involved has not been adequately explained by these cells' potential role in modulating system insulin sensitivity and islet regeneration. In this study, we demonstrated adipose-derived mesenchymal stem cells (ASCs) produced significantly lower blood glucose via promoting hepatic glycogen synthesis and inhibiting hepatic glucose production within 24 h after infusion in T2DM rats. In vitro, HepG2 cells treated with palmitate (PA) were used as a model of hepatic glucose metabolism disorder to confirm that ASCs stimulates the phosphorylation of hepatic AMP-activated protein kinase (AMPK) to restores hepatic glucose metabolism in type 2 diabetes. In summary, this study indicated that ASCs improve hyperglycemia via regulating hepatic glucose metabolism. Additionally, the effect of ASCs on hepatic glucose metabolism depended on the AMPK signaling pathway. Thus, this is the new research of the molecular mechanisms of MSCs administration to improve glucose metabolism, and it may indicate a new treatment target of MSCs in T2DM.